Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
July 02 2024 - 1:58PM
Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF)
(CSE: RVV) (FRANKFURT:31R), a specialty life sciences company
focused on the research and development of therapeutics and
diagnostics for infectious diseases, medical countermeasures, and
rare disorders, announced today an update on the research study
evaluating Bucillamine as a potential treatment for nerve agent
exposure, in partnership with Defence R&D Canada – Suffield
Research Centre (“DRDC”), an agency of the Canadian Department of
National Defence. The DRDC is investigating pharmacological
compounds, including Bucillamine, that can mitigate nerve agent
induced brain injury. Control studies have been initiated and the
DRDC expects to evaluate the data this month. Treatment studies
will follow after the conclusion of the control group evaluation.
The research study is expected to be completed in August 2024.
Nerve agents are chemicals that affect the nervous system. Nerve
agents are highly toxic regardless of the route of exposure. The
main chemical nerve agents that are man-made and manufactured for
use in chemical warfare are sarin, soman, tabun and VX. These nerve
agents are known to be present in military stockpiles. Exposure to
nerve agents can occur due to chemical warfare or accidental
release from a military storage facility. Exposure to nerve agents
can cause tightness of the chest, excessive salivation, abdominal
cramps, diarrhea, blurred vision, tremors, and death.
Recent studies have shown that antioxidant compounds such as
n-acetylcysteine (“NAC”) could be beneficial in limiting seizure
activity and improving the anticonvulsant efficacy of
GABA-mediating drugs such as diazepam.
Bucillamine is a significantly more effective antioxidant than
NAC and has the potential to provide increased efficacy against
seizure activity while limiting the anticoagulant and bleeding
event liability observed with NAC. The overall objective of the
research project is to investigate pharmacological means for
neuroprotection of GABA(A) receptors, which are required for the
effectiveness of currently fielded anticonvulsant therapies.
Bucillamine and NAC will be evaluated to determine the effect on
GABA(A) receptor endocytosis and the effect on diazepam
effectiveness in terminating seizures. Any additional antioxidant
effects on seizure activity and survival will also be assessed. The
results from this research study, if promising, will determine
further studies to facilitate FDA and Health Canada approvals for
the use of Bucillamine in nerve agents or organophosphate pesticide
poisoning. Also, the Company may explore the potential of
Bucillamine for traumatic brain injury caused by concussive or
explosive forces.
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the
research and development of therapeutics and diagnostics for
infectious diseases, medical countermeasures, and rare disorders.
Revive prioritizes its drug development efforts to take advantage
of several regulatory incentives awarded by the FDA, such as
Emergency Use Authorization, Orphan Drug, Fast Track, and
Breakthrough Therapy designations. Currently, the Company is
exploring the use of Bucillamine for the potential treatment of
nerve agent exposure and long COVID. Revive is also advancing the
development of Psilocybin-based therapeutics through various
programs. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael FrankChief Executive OfficerRevive Therapeutics Ltd.Tel:
1 888 901
0036Email: mfrank@revivethera.comWebsite: www.revivethera.com
Neither the Canadian Securities Exchange nor its
Regulation Services Provider has reviewed or accepts responsibility
for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information’ within
the meaning of applicable Canadian securities legislation. These
statements relate to future events or future performance. The use
of any of the words “may”, “could”, “intend”, “expect”, “believe”,
“will”, “projected”, “estimated” and similar expressions and
statements relating to matters that are not historical facts are
intended to identify forward-looking information and are based on
Revive’s current belief or assumptions as to the outcome and timing
of such future events. Forward looking information in this press
release includes information with respect to the Company’s
cannabinoids, psychedelics and infectious diseases programs.
Forward-looking information is based on reasonable assumptions that
have been made by Revive at the date of the information and is
subject to known and unknown risks, uncertainties, and other
factors that may cause actual results or events to differ
materially from those anticipated in the forward-looking
information. Given these risks, uncertainties and assumptions, you
should not unduly rely on these forward-looking statements. The
forward-looking information contained in this press release is made
as of the date hereof, and Revive is not obligated to update or
revise any forward-looking information, whether as a result of new
information, future events or otherwise, except as required by
applicable securities laws. The foregoing statements expressly
qualify any forward-looking information contained herein. Reference
is made to the risk factors disclosed under the heading “Risk
Factors” in the Company's management's discussion and analysis for
the three and nine months ended March 31, 2024 ("MD&A"), dated
May 28, 2024, which is available on the Company's profile at
www.sedarplus.ca.